Big Data Analysis and Management

Big Data Analysis and Management

Context: A major US pharmaceutical manufacturer had been encouraged by regulators and payers to integrate a recently approved combinational diagnostic into the care delivery pathway of a gene therapy for the treatment of an aggressive monogenic disease. The manufacturer has limited experience with combinational diagnostics and was concerned how the product development would impact their reimbursement forecasts.

Solution: IPAV conducted a review of the market and regulatory landscape for combinational therapies, complemented by targeted internal training for key staff critical to successful product repositioning. Thereafter, IPAV conducted a detailed sensitivity analysis to evaluate time impact of a number of metrics – including Rx and Dx price, Dx sensitivity, Rx efficacy – to determine the optimal pricing and reimbursement coding for the new combinational therapy.

Outcome: The client delivered the introduction of the combinational diagnostics ahead of time and under budget. IPAV is now working with both the Rx and Dx manufacturers to evaluate opportunities for future strategic collaborations.

Related Projects